Injectable Cytotoxic Drugs Market Size to Reach USD 30.85 billion by 2032; Increase in Cases of Rheumatoid Arthritis and Cancer to Augment Market Progress

The global injectable cytotoxic drugs market size reached USD 18.29 billion in 2023 and is anticipated to touch USD 19.03 billion in 2024. The market is predicted to be valued at USD 30.85 billion by 2032, recording a CAGR of 6.2% over 2024-2032.

Fortune Business Insights™ presents this information in its latest report titled “Injectable Cytotoxic Drugs Market Size, Share & Industry Analysis, By Drug Class (Alkylating Drugs, Cytotoxic Antibodies, Antimetabolites, Plant Alkaloids, and Others), By Application (Oncology, Rheumatoid Arthritis, Multiple Sclerosis, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2024-2032”.

The cases of various chronic diseases, such as cancer, are increasing at an alarming rate every year worldwide. This surge in cases has led to a growing demand for injectable cytotoxic drugs, which are widely used to treat these ailments. Medical professionals prescribe these medicines as the first line of treatment due to their cellular regeneration feature that can eliminate cancerous cells. These factors are anticipated to fuel the injectable cytotoxic drugs market growth.

Decrease in Demand for Non-Essential Therapies Slowed Market Growth during COVID-19

A decrease in the demand for non-essential therapies significantly slowed down the market's growth during 2020 and 2021 due to factors such as changes in bio-manufacturing and disruptions in the supply chain. Moreover, a vast majority of the healthcare sector allocated its vital resources to treat COVID-19-positive patients, which resulted in the postponement of many non-essential treatments. This factor negatively impacted the use of injectable cytotoxic drugs.

Merck KGaA Announced Acquisition of VelosBio to Boost Former’s Product Portfolio

Merck KGaA announced that it had acquired VelosBio, which is a privately owned clinical-stage biopharmaceutical firm. This move helped the company boost its portfolio of cancer-based medicines.

Increase in Cases of Rheumatoid Arthritis and Cancer to Augment Market Progress

The increase in cases of rheumatoid arthritis and cancer is expected to augment market progress. The incidence of cancer is rising worryingly globally, making it the second leading cause of death after cardiovascular disease. Various environmental factors contribute to the rise in cancer cases, including urbanization-related pollution, tobacco smoking, and extreme changes in dietary habits. Additionally, the number of people suffering from rheumatoid arthritis is also on the rise, further accelerating the sales of injectable cytotoxic drugs in the coming years.

Key Market Players to Introduce Affordable Treatments to Expand Geographic Presence

Key market players are set to introduce affordable treatments to expand their geographic presence. The market's competitive landscape is highly fragmented due to the presence of reputed domestic and international companies. Johnson & Johnson Services, Inc. secured a dominant position in this market in 2022 by increasing its focus on mergers and acquisitions to expand its product portfolio. Moreover, many leading firms are launching cost-effective treatments to expand patients’ access and improve their quality of life, a move that can also help the companies increase their market share and expand their geographic presence.

Key Industry Development

• June 2023: The U.S. FDA temporarily permitted the import of 50-milligram vials of cisplatin, an injectable chemotherapy drug. This move was intended to bolster supplies within the U.S.

List of Key Players Profiled in this Market Report

• Johnson and Johnson Services Inc., (U.S.)
• Sanofi (France)
• Eli Lilly and Company (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Novartis AG (Switzerland)
• Pfizer, Inc. (U.S.)
• Merck & Co. Inc. (U.S.)
• Amgen, Inc. (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/injectable-cytotoxic-drugs-market-104705

Further Report Findings:

• North America dominated the global injectable cytotoxic drugs market share in 2022 and is expected to grow at a considerable pace in the coming years due to a major rise in the number of cancer patients. Moreover, pharmaceutical companies across the region are striving to increase patients’ access to various cancer drugs, thereby improving regional market growth.
• The market in Asia Pacific is also anticipated to display notable growth during the forecast timeline as the number of patients suffering from cancer and other chronic diseases is increasing. Moreover, regional governments are boosting their investments in healthcare, which will further amplify regional market development.
• The oncology application segment dominated the global market in 2022. The segment’s growth is primarily due to the growing incidence of cancer and the rising consumption of oncology medicines to treat the ailment. Moreover, the growing reliance of patients on cytotoxic medicines for the treatment of cancer will also boost the segment’s growth.

Table of Segmentation